SecBot SecBot
SECBOTREPLAY Home › Report › MRNA

MRNA · Q3 revenue +29% YoY

Moderna, Inc. · 8-K filed Nov 6, 2026 at 06:47 ET

At the news

BULLISHIMPACT 7/10

8-K filed Nov 6, 2026 at 06:47 ET

Moderna reported Q3 2026 revenue of $1.313B (consensus $890.2M) and GAAP diluted EPS of $0.38 (consensus $-1.25), a significant beat driven by higher COVID vaccine sales in international markets. The company raised its full-year 2026 revenue growth outlook to 15%-25% from up to 10%, improved its year-end cash balance forecast to $8.1B-$8.3B, and highlighted the FDA approval of mFLUSIVA and positive Phase 3 data for intismeran in melanoma.

  • Q3 2026 total revenue $1.313B, up 29% YoY from $1.016B
  • GAAP diluted EPS $0.38, compared to a loss per share of $(0.51) in Q3 2025
  • Net income of $162M, compared to a net loss of $(200M) in Q3 2025
  • 2026 revenue growth outlook raised to 15%-25%, exceeding prior expectation of up to 10% growth

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access